unique_id,Statement,Resource,LoE/GoR,Consensus,Type,Section
c1bad423-c0bb-49dd-add3-a9400c324a41,"Visceral crisis is defined as severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important organ compromise leading to a clinical indication for the most rapidly efficacious therapy.
Examples: Liver visceral crisis: rapidly increasing bilirubin >1.5x ULN in the absence of Gilbert's syndrome or biliary tract obstruction. Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,97%,Guideline statement,ABC definitions
473820d0-e06e-4bf0-b8e6-10dab65a6f47,"Primary endocrine resistance is defined as relapse while on the first 2 years of adjuvant ET, or PD within the first 6 months of first-line ET for ABC, while on ET.
Secondary endocrine resistance is defined as relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD >=6 months after initiating ET for ABC, while on ET.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,67%,Guideline statement,ABC definitions
410e267a-37a1-494f-a2d1-ad185503bfda,"Oligometastatic disease is defined as low-volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ), potentially amenable for local treatment aimed at achieving a complete remission status.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,78%,Guideline statement,ABC definitions
e31bb146-4cfc-484d-a11b-5ce923ff0a3c,"Patients with multiple chronic conditions are defined as patients with additional comorbidities (e.g. cardiovascular, impaired renal or liver function, autoimmune disease) making it difficult to account for all of the possible extrapolations to develop specific recommendations for care.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Guideline statement,ABC definitions
e2d10088-2b45-47be-a7d8-c56be875b23b,"Adequate OFS in the context of ABC
Adequate OFS for ABC premenopausal patients can be obtained through bilateral ovariectomy, continuous use of LHRH agonists or OFA through pelvic RT (the latter is not always effective and therefore is the least preferred option).
If an LHRH agonist is used in this age group, it should usually be given on a q4w basis to optimise OFS.
Efficacy of OFS must be initially confirmed analytically through serial evaluations of serum estradiol, even in the presence of amenorrhoea, especially if an AI is administered.
As all endocrine interventions for premenopausal patients with endocrine-responsive ABC require indefinite OFS, choosing one method over the other requires a balance of the patient's wish for potentially preserving fertility, compliance with frequent injections over a long period of time, risk of inadequate estrogen level suppression and cost.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/A
II/B
Expert opinion/B","85%
85%
85%",Guideline statement,ABC definitions
09bb63db-46c4-42c5-8bf1-b9d1452d2ae8,"Maintenance therapy: in the context of ABC guidelines, maintenance therapy refers to the continuation of anti-HER2 therapy and/or ET after discontinuation of ChT.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Guideline statement,ABC definitions
3e756b7a-7ab5-4f42-bf39-b941a60ae625,Integrative medicine: complementary and integrative medicine (CIM) represents the use of complementary treatments side by side with conventional approaches in a proper therapeutic environment.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Guideline statement,ABC definitions
120d38c6-6731-4761-9d89-146f013707e3,"The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary team (including but not restricted to medical, radiation and surgical oncologists, imaging experts, pathologists, gynaecologists, psycho-oncologists, social workers, nurses and palliative care specialists) is crucial.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Guideline statement,General guidelines
58d08154-fa77-43ef-962d-e8131ee1846e,"From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care and symptom-related interventions as a routine part of their care. The approach must be personalised to meet the needs of the individual patient.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Guideline statement,General guidelines
ab8d873b-6e14-4ae8-a86d-d4aa840d828d,"Following a thorough assessment and confirmation of MBC, the potential treatment goals of care should be discussed. Patients should be told that MBC is incurable but treatable, and that some patients can live with MBC for extended periods of time (many years in some circumstances).
This conversation should be conducted in the accessible language, respecting patient privacy and cultural differences, and whenever possible, written information should be provided.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,97%,Guideline statement,General guidelines
9cffff38-9e28-44bb-a4db-42791a4c31f4,"All ABC patients should be offered comprehensive, culturally sensitive, up-to-date and easy-to-understand information about their disease and its management.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,97%,Guideline statement,General guidelines
da15f39c-0c07-40ec-b09e-ed25eb7db2a5,"Patients (and their families, caregivers or support network, if the patient agrees) should be invited to participate in the decision-making process at all times. When possible, patients should be encouraged to be accompanied by persons who can support them and share treatment decisions (e.g. family members, caregivers, support network).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Guideline statement,General guidelines
4ef062d6-42f7-4a05-bee9-3adb0e0e4c31,"Every ABC patient must have access to optimal cancer treatment and supportive care according to the highest standards of patient-centred care, as defined by:*Open communication between patients and their cancer care teams as a primary goal.*Educating patients about treatment options and supportive care, through development and dissemination of evidence-based information in a clear, culturally appropriate form.*Encouraging patients to be proactive in their care and to share decision making with their healthcare providers.*Empowering patients to develop the capability of improving their own QoL within their cancer experience.*Always taking into account patient preferences, values and needs as essential to optimal cancer care.*Patients should have easy access to well-designed clinical studies since these are crucial for further improvement in the management of ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Guideline statement,General guidelines
8c09330c-9a9a-45d1-ad2f-d54795c35372,"Every ABC patient should:*Have access to the most up-to-date treatments and innovative therapies at accessible breast units/centres.*Be treated in specialist breast units/centres/services (SBUs) by a specialised multidisciplinary team including specialised side-effects management and a nurse experienced in the treatment of ABC.*Survivorship issues and palliative care should be addressed and offered at an early stage.*A quality assurance programme covering the entire breast cancer pathway from screening and diagnosis to treatment, rehabilitation, follow-up and palliative care, including services and support for ABC patients and their caregivers, should be implemented by SBUs.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","Expert opinion/A
I/A
Expert opinion/A
Expert opinion/B",100%,Guideline statement,General guidelines
bc5a508e-cc7f-4fee-9a4b-ad680a27564b, Strong consideration should be given to the use of validated PROMs for patients to record the symptoms of disease and side-effects of treatment experienced as a regular part of clinical care. These PROMs should be simple and user-friendly to facilitate their use in clinical practice and thought needs to be given to the easiest collection platform e.g. tablets or smartphones. Systematic monitoring would facilitate communication between patients and their treatment teams by better characterising the toxicities of all anticancer therapies. This would permit early intervention of supportive care services enhancing QoL.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/C,87%,General statements: QoL,General guidelines
97db469d-8dfd-4dfc-957f-e447a34fe72d," Specific tools for evaluation of QoL in ABC patients should be developed.
Until then, trials evaluating QoL in this setting should use standardised PROs (instead of focusing exclusively on CTCAEs) and incorporate site- and treatment-specific modules or subscales that exist both in the EORTC and FACT systems.
Additionally, attention needs to be paid to collection methods, timing of assessments and handling of missing data. More sophisticated statistics should also be employed to ensure that clinicians have better, reliable data to help patients when choosing between treatment options.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","Expert opinion/A
Expert opinion/A
Expert opinion/A","100%
100%
100%",General statements: QoL,General guidelines
834d5d9c-ef63-483d-9533-f10f516e2e48," After appropriate informed consent, inclusion of patients in well-designed, prospective, independent trials must be a priority whenever such trials are available and the patient is willing to participate.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,General statements: clinical trials,General guidelines
b8f896f3-e2b7-426a-a236-14cfac9ab03e," The ABC community strongly calls for clinical trials addressing important unanswered clinical questions in this setting, and not just for regulatory purposes. Clinical trials should continue to be performed, even after approval of a new treatment, to provide real-world data on its performance, efficacy and toxicity.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,General statements: clinical trials,General guidelines
a8af5181-d27f-4d8a-bd20-68647c3ee29b," The medical community is aware of the problems raised by the cost of ABC treatment. Balanced decisions should be made in all instances; patients' well-being, length of life and preferences should always guide decisions.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,General statements: affordability/cost effectiveness,General guidelines
b74f01fe-d3ef-4085-b3d0-f57457e954d3," We strongly recommend the use of objective scales, such as the ESMO-MCBS or the ASCO Value Framework, to evaluate the real magnitude of benefit provided by a new treatment and help prioritise funding, particularly in countries with limited resources.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,88%,General statements: affordability/cost effectiveness,General guidelines
8a78dd25-6d3c-4c4f-9710-cd58aa6017ae," The ABC community strongly supports the use of biosimilars both for treatment of breast cancer (i.e. trastuzumab) and for supportive care (i.e. growth factors). To be used, the biosimilar must be approved after passing the stringent development and validation processes required by the EMA or the FDA or other similarly strict authority.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,90%,General statements: affordability/cost effectiveness,General guidelines
95275c83-290a-4b01-88a6-ff858e5048c8," As survival is improving in many patients with ABC, consideration of survivorship issues should be part of the routine care of these patients. Health professionals should therefore be ready to change and adapt treatment strategies to disease status, treatment of adverse effects and QoL, patients' priorities and life plans. Attention to chronic needs for home and family care, job and social requirements, should be incorporated in the treatment planning and periodically updated.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,95%,General statements: survivorship,General guidelines
48d0577b-8d45-414e-9257-2340aa0883f1," ABC patients who desire to work or need to work for financial reasons should have the opportunity to do so, with needed and reasonable flexibility in their working schedules to accommodate continuous treatment and hospital visits.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,General statements: survivorship,General guidelines
fceab92f-45a7-4c6a-83ad-f42265270aba, ABC patients with stable disease being treated as a 'chronic condition' should have the option to undergo breast reconstruction if clinically appropriate.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,82%,General statements: survivorship,General guidelines
1e384a9b-f130-439d-8887-36b81eac1c2d,"In ABC patients with long-standing stable disease or complete remission, breast imaging is an option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,83%,General statements: survivorship,General guidelines
cd707e65-88f1-452a-bfe0-bad600f8c0f6,Breast imaging should also be performed when there is a suspicion of locoregional progression.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,General statements: survivorship,General guidelines
73da8eb6-7165-4085-886c-3b3dadfef4a0," Fertility preservation: the impact of the anticancer therapies on fertility should be discussed with all women with ABC of childbearing age, and their partners, before the start of treatment. The discussion must also include appropriate information about the prognosis of the disease and the potential consequences of pregnancy (e.g. stopping ongoing treatment).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,100%,General statements: survivorship,General guidelines
9fbf3095-d209-4256-a3e2-3d064ddd5d95," Specialised oncology nurses (if possible specialised breast nurses) should be part of the multidisciplinary team managing ABC patients. In some countries, this role may be played by a physician assistant or another trained and specialised healthcare practitioner.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,92%,General statements: other,General guidelines
4cb352e7-5bc0-4c12-8392-4978c4b7e6c7, The use of telemedicine in oncology to help management of patients with ABC living in remote places is an important option to consider when geographic distances are a problem and provided that issues of connectivity are solved.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,93%,General statements: other,General guidelines
67e1cfc7-ccb0-4bc7-a19d-5b45c9108da2," Minimal staging work-up for ABC includes a history and physical examination, haematology and biochemistry tests and imaging of the chest, abdomen and bones.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,67%,Image and disease assessment guidelines,Assessment and treatment general guidelines
d652370b-bb79-4799-bb41-ffd65a48df75," Brain imaging should not be routinely performed in asymptomatic patients. This approach is applicable to all patients with ABC, including those with HER2-positive and/or triple-negative ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/D,94%,Image and disease assessment guidelines,Assessment and treatment general guidelines
bd98450e-1e76-415b-b6e3-7f4b9cf5ac03," The clinical value of tumour markers is not well established for diagnosis or follow-up after adjuvant therapy, but their use (if elevated) as an aid to evaluate response to treatment, particularly in patients with non-measurable metastatic disease, is reasonable. An increase in tumour markers alone should not be used to initiate a change in treatment.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/C,89%,Image and disease assessment guidelines,Assessment and treatment general guidelines
b158c4f6-8c05-46be-a3b9-93419754d99d," Evaluation of response to therapy should generally occur every 2-4 months for ET or after 2-4 cycles for ChT, depending on the dynamics of the disease, the location and extent of metastatic involvement and type of treatment. Imaging of a target lesion may be sufficient in many patients. In certain patients, such as those with indolent disease, less frequent monitoring is acceptable. Additional testing should be performed in a timely manner, irrespective of the planned intervals, if PD is suspected or new symptoms appear. A thorough history and physical examination must always be performed.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,81%,Image and disease assessment guidelines,Assessment and treatment general guidelines
7764b798-2360-41f2-a2aa-a7c351406b3e," A biopsy (preferably providing histology) of a metastatic lesion should be performed, if easily accessible, to confirm diagnosis, particularly when metastasis is diagnosed for the first time.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,98%,Biopsy guidelines,Assessment and treatment general guidelines
d1991d1c-ea77-41a7-ba46-2b0ac6dcf1e8," Biological markers (especially HR and HER2) should be reassessed at least once in the metastatic setting, if clinically feasible. Depending on the metastatic site (e.g. bone tissue), technical considerations need to be discussed with the pathologist.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,98%,Biopsy guidelines,Assessment and treatment general guidelines
e0453b84-0d93-4af3-a75f-1fe956e6aaa7," If the results of tumour biology in the metastatic lesion differ from the primary tumour, it is currently unknown which result should be used for treatment decision making. Since a clinical trial addressing this issue is difficult to undertake, we recommend considering the use of targeted therapy (ET and/or anti-HER2 therapy) when receptors are positive in at least one biopsy, regardless of timing.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,87%,Biopsy guidelines,Assessment and treatment general guidelines
d6daf329-800f-4486-8fca-922376353c2d," To date, the removal of the primary tumour in patients with de novo stage IV breast cancer has not been associated with prolongation of survival, with the possible exception of the subset of patients with bone-only disease. However, it can be considered in selected patients with controlled systemic disease, particularly to improve QoL, always taking into account the patient's preferences.
Of note, some studies suggest that surgery is only valuable if performed with the same attention to detail (e.g. complete removal of the disease) as in patients with early-stage disease.
Additional prospective clinical trials evaluating the value of this approach, the best candidates and best timing are currently ongoing.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/C
II/B","70%
70%",Locoregional treatment general guidelines,Assessment and treatment general guidelines
3938bd32-c3bd-4985-a191-1f5c5949be51," A small but very important subset of patients with ABC, for example those with oligometastatic disease or low-volume metastatic disease that is highly sensitive to systemic therapy, can achieve complete remission and a long survival. A multimodal approach, including locoregional treatments with curative intent, should be considered for these selected patients. A prospective clinical trial addressing this specific situation is needed.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,91%,Locoregional treatment general guidelines,Assessment and treatment general guidelines
2c6480c5-c43d-4a02-9d8c-a03d84b25532," Treatment choice should take at least these factors into account:
HR and HER2 status and germline BRCA status, PIK3CA in HR-positive and PD-L1 in TNBC, if targeted therapies are accessible. Previous therapies and their toxicities, DFI, tumour burden (defined as number and site of metastases), biological age, PS, comorbidities (including organ dysfunctions), menopausal status (for ET), the need for rapid disease/symptom control, socio-economic and psychological factors, available therapies in the patient's country and patient's preference.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,95%,Systemic treatment general guidelines,Assessment and treatment general guidelines
b334a8fe-f136-422f-9436-4b8363b6718a, The age of the patient should not be the sole reason to withhold effective therapy (in elderly patients) nor to overtreat (in young patients). Age alone should not determine the intensity of treatment.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/E,100%,Systemic treatment general guidelines,Assessment and treatment general guidelines
8dc9e4a3-12c5-4e27-b0ec-3480c10bd662," Both combination and sequential, single-agent ChT are reasonable options. Based on the available data, we recommend sequential monotherapy as the preferred choice for ABC. Combination ChT should be reserved for patients with rapid clinical progression, life-threatening visceral metastases or the need for rapid symptom and/or disease control.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,96%,ChT general guidelines,Assessment and treatment general guidelines
d4b963b5-0681-457d-ba36-78df7eb79658," In the absence of medical contraindications or patient concerns, anthracycline- or taxane-based regimens, preferably as single agents, would usually be considered as first-line ChT for HER2-negative ABC in those patients who have not received these regimens as (neo)adjuvant treatment and for whom ChT is appropriate. Other options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,71%,ChT general guidelines,Assessment and treatment general guidelines
a75915f7-1dc2-4a2c-ab0a-47230e080399," In patients with taxane-naive and anthracycline-resistant ABC or with anthracycline maximum cumulative dose or toxicity (i.e. cardiac) who are being considered for further ChT, taxane-based therapy, preferably as single agent, would usually be considered as the treatment of choice. Other options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,59%,ChT general guidelines,Assessment and treatment general guidelines
1bb01f72-d2e1-4f20-a7fa-0f1f065ad803," In patients pretreated (in the adjuvant and/or metastatic setting) with an anthracycline and a taxane, single-agent capecitabine, vinorelbine or eribulin are the preferred choices. Additional choices include gemcitabine, platinum agents, a different taxane and liposomal anthracyclines. The decision should be individualised and take into account different toxicity profiles, previous exposure, patient preferences and country availability.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,77%,ChT general guidelines,Assessment and treatment general guidelines
1561e7e3-1d43-42ee-8b3c-553706b83b5d," If given in the adjuvant setting, a taxane can be re-used as first-line therapy, particularly if there has been at least 1 year of DFI.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,92%,ChT general guidelines,Assessment and treatment general guidelines
1bc000fe-3e20-475a-a384-8a36106073a3," If given in the adjuvant setting, provided that maximum cumulative dose has not been achieved and there are no cardiac contraindications, anthracyclines can be re-used in ABC, particularly if there has been at least 1 year of DFI.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,93%,ChT general guidelines,Assessment and treatment general guidelines
7afb7bed-987a-43c2-9fe6-356bdc7d3f71," Metronomic ChT is a treatment option for patients not requiring rapid tumour response. Available regimens are CM (low-dose oral cyclophosphamide and methotrexate), capecitabine or oral vinorelbine-based regimens. Randomised trials are needed and underway to accurately compare metronomic ChT with standard dosing regimens.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,98%,ChT general guidelines,Assessment and treatment general guidelines
ea1b66d8-c45e-47dc-9a47-5937e9249a06, Duration of each regimen and the number of regimens should be tailored to each individual patient.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,96%,ChT general guidelines,Assessment and treatment general guidelines
3c2a8d89-da48-4a81-b9d4-6db278e7a567," Usually, each regimen (except anthracyclines) should be given until PD or unacceptable toxicity.
What is considered unacceptable should be defined together with the patient.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,72%,ChT general guidelines,Assessment and treatment general guidelines
8b33a2fe-6d9f-41af-85d5-d2b15e1b1b30," Bevacizumab combined with ChT as first-line therapy for ABC provides a moderate benefit in PFS and no benefit in OS. The absence of known predictive factors for bevacizumab efficacy renders recommendations on its use difficult. Bevacizumab can only therefore be considered as an option in selected cases and only in the first-line setting.
ESMO-MCBS v1.1 score: 2","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/C,"Yes: 42%
No: 53%",Other agents,Assessment and treatment general guidelines
e294781c-939e-4836-a7d7-b2d80d166f0d,"ET is the preferred option for HR-positive disease, even in the presence of visceral disease, unless there is visceral crisis, for pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,93%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
896380f5-cfe2-444e-a093-b984dcf3714c,"Many trials in ER-positive ABC have not included premenopausal women. Despite this, we recommend that young women with ER-positive ABC should have adequate OFS/OFA and then be treated in the same way as postmenopausal women, with endocrine agents with or without targeted therapies.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,95%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
30c9ba07-bca0-492e-b601-22b9960a2149,"Future trials exploring new endocrine-based strategies should be designed to allow for enrolment of both pre- and postmenopausal women, and men.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,92%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
b42668e7-2a05-4eb4-aee6-e12c7cd955fb,"For premenopausal women, for whom ET was decided, OFS/OFA combined with additional endocrine-based therapy is the preferred choice.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,93%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
b82c1602-0a49-4086-9ee6-7e0d39975e32,"OFA by laparoscopic bilateral oophorectomy ensures definitive estrogen suppression and contraception, avoids the potential initial tumour flare seen with an LHRH agonist and may increase eligibility for clinical trials. Patients should be informed of the options for OFS/OFA and decisions should be made on a case-by-case basis.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,91%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
3addeb69-d774-4078-9fa6-ea30e7e4690c,"Single-agent tamoxifen is the only available endocrine option for premenopausal women who decline OFS/OFA, but the panel believes it is a less effective option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,92%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
e8aa8d9a-4053-48f9-b742-24c279dc0705,"The preferred first-line agent depends on the type and duration of adjuvant ET as well as the time elapsed from the end of adjuvant ET; it can be an AI, tamoxifen or fulvestrant for pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,84%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
42adeadb-973e-4a76-bce3-8e6f1ae0732e,"A CDK4/6 inhibitor combined with ET is the standard of care for patients with ER-positive/HER2-negative ABC, since it achieves a substantial PFS benefit, significantly increases OS and either maintains or improves QoL.
The CDK4/6 inhibitor can be combined with an AI or with fulvestrant, in de novo or recurrent ABC, in first or second line and in cases of primary or secondary resistance (defined as per ABC guidelines).
This recommendation applies to postmenopausal women, to premenopausal women in combination with an LHRH agonist and to men preferably in combination with an LHRH agonist.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,97%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
76523646-70b0-4b91-945b-7e5811994caa,"The ESMO-MCBS scores for the use of a CDK4/6 inhibitor combined with ET for ABC patients vary according to the setting and drug.
They are the following, with the current available data and follow-up:*Palbociclib + AI first line: efficacy score: 3 (PFS); no improved QoL; ESMO-MCBS v1.1 score: 3*Abemaciclib + AI first line: efficacy score: 3 (PFS); no QoL reported; ESMO-MCBS v1.1 score: 3*Ribociclib + AI first line postmenopausal: efficacy score: 3 (PFS); no improved QoL; ESMO-MCBS v1.1 score: 3*Ribociclib + ET first line premenopausal: efficacy score: 4 (PFS & OS); QoL improved; ESMO-MCBS v1.1 score: 5*Palbociclib + fulvestrant second line: efficacy score: 3 (PFS & OS); improved QoL; ESMO-MCBS v1.1 score: 4*Ribociclib + fulvestrant first, second line: efficacy score: 4 (PFS & OS); no improvement in QoL; ESMO-MCBS v1.1 score: 4*Abemaciclib + fulvestrant second line: efficacy score: 4 (PFS & OS); no QoL benefit; ESMO-MCBS v1.1 score: 4Of note, the three CDK4/6 inhibitors have not been compared head-to-head within a clinical trial.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
8c223b01-aaf9-4edb-b106-9cac96bf83b2,"It remains unclear if CDK4/6 inhibitors should be preferably administered in the first- or second-line setting. However, the majority of panellists preferred giving a CDK4/6 inhibitor in the first-line setting for the majority of their patients.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
e91aa4fa-a40e-406c-bff2-1641c6778851,"There are no data supporting the use of a combination of CDK4/6 inhibitor and ET as maintenance therapy after ChT.
Maintenance therapy, in this situation, should be carried out with ET alone.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/D,66%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
b3425c90-5f4b-4214-b2e3-01eba4dda272,"The addition of everolimus to an AI is a valid option for some patients [for pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women] previously exposed to or naive of (in case CDK4/6 inhibitors are not available) ET, since it significantly prolongs PFS, albeit without evidence of an OS benefit. ESMO-MCBS v1.1 score: 2
The decision to treat must take into account the toxicities associated with this combination, the lack of a statistically significant OS benefit, cost and availability.
Tamoxifen or fulvestrant can also be combined with everolimus.
Adequate prevention, close monitoring and proactive treatment of AEs is needed, particularly in older patients treated with everolimus due to the increased incidence of toxic deaths reported in the BOLERO-2 trial.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/B
II/B
I/B","88%
80%
97%",Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
eb058049-1999-428c-846d-fb1626c8a693,"Everolimus and CDK4/6 inhibitors should not be used after PD on that specific agent (i.e. beyond progression), outside a clinical trial.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/E,74%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
2892502c-ce71-4baf-9bee-c067627236ca,"Alpelisib with fulvestrant is a treatment option for patients with PIK3CA-mutated tumours (in exons 9 or 20), previously exposed to an AI and with appropriate HbA1c levels, since it provided about 5 months of benefit in median PFS.
The decision to give alpelisib should take into consideration the inclusion/exclusion criteria in the SOLAR-1 study (i.e. pre-existing diabetes and baseline HbA1c), as well as the toxicity profile of alpelisib.
Its efficacy after exposure to CDK4/6 inhibitors is unknown, since only 6% of patients in the SOLAR-1 trial had been previously treated with those agents. ESMO-MCBS v1.1 score: 3","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,88%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
8609068f-41e8-48dd-bd7d-7bc74629f8aa,Patients receiving alpelisib in combination with ET for PIK3CA-mutated ABC should be instructed to take non-sedating antihistamines to prevent rash at the start of therapy. Antihistamines can be discontinued after 4 weeks as the risk for rash is primarily in the first 2 weeks of therapy.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,93%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
3dec1408-f875-4ac2-b3d0-8d1b9f3746d9,"At present, no validated predictive biomarkers other than hormone receptor status exist to identify patients who will/will not benefit from the addition of a CDK4/6 inhibitor or an mTOR inhibitor to ET and none of the studied biomarkers is ready for use in clinical practice. Research efforts must continue.
Alpelisib should only be used in cases of PIK3CA-mutated tumours.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/E
II/A","95%
95%",Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
f3def87a-90e9-40a0-9773-4954a2008197,"The combination of a non-steroidal AI and fulvestrant as first-line therapy for postmenopausal patients resulted in significant improvement in both PFS and OS compared with AI alone in one phase III trial and no benefit in a second trial with a similar design. Notably, a suboptimal dose of fulvestrant was used in the study that demonstrated benefit.
Subset analysis suggested that the benefit was limited to patients without prior exposure to adjuvant ET (tamoxifen). Based on these data, combination ET may be offered to some patients with ABC without prior exposure to adjuvant ET in cases where a CDK4/6 inhibitor will not be given. ESMO-MCBS v1.1 score: 2
Comparative data between this combination and a CDK4/6 inhibitor with ET are not available.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/D,"Yes: 38%
No: 60%
Abstain: 2%",Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
6104b18f-a74e-45d5-aab9-9039246e1d36,"The optimal sequence of endocrine-based therapy is uncertain. It depends on which agents were previously used [in the (neo)adjuvant or advanced settings], duration of response to those agents, burden of the disease, patients' preference and availability. Available options for first and second line include AI/fulvestrant + CDK4/6 inhibitor, AI/tamoxifen/fulvestrant + everolimus, fulvestrant + alpelisib (for PIK3CA-mutated tumours), AI, tamoxifen, fulvestrant. This applies to pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
1a03b24c-8bd4-48f0-9052-b8cc4df70994,"Options for treatment of ER-positive disease beyond second line include single agents not previously used (NSAI, SAI, tamoxifen, fulvestrant, megestrol acetate, low-dose estrogen). Single-agent abemaciclib is also a potential option.
Challenging a patient with an agent on which the disease previously progressed after an initial response is occasionally considered, but there are no robust data to support this approach. This applies to pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","II/B
Expert opinion/B","98%
98%",Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
6a356650-e5ec-4838-9a74-9e00db348539,"Trials comparing the different combinations of endocrine + targeted agents with single-agent ChT are ongoing.
Initial results from phase II and III randomised trials comparing combinations of endocrine + targeted agents to single-agent ChT do not show significant differences in terms of efficacy, and the former compares favourably in terms of safety.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/B,Not voted,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
89e090f9-1a23-4c34-8dae-ab685801b4b7,Concomitant ChT and ET has not shown a survival benefit and should not be performed outside a clinical trial.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/D,100%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
7bdf0c42-3d27-4ede-be61-7c85ae2e3182,"Endocrine treatment after ChT (maintenance ET) to maintain benefit is a reasonable option, though it has not been properly assessed in randomised trials.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/B,88%,Guideline statement,ER-positive/HER2-negative (luminal-like) ABC
32f891f6-8a18-4c48-8556-462fad6622fc,"Anti-HER2 therapy should be offered early (as first line) to all patients with HER2-positive ABC, except in the presence of contraindications to the use of such therapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,98%,Guideline statement,HER2-positive ABC
c000d02d-900f-456d-a3bc-97c714598a89,"Patients progressing on an anti-HER2 therapy combined with a cytotoxic or endocrine agent should be offered additional anti-HER2 therapy with subsequent treatment, except in the presence of contraindications, since it is beneficial to continue suppression of the HER2 pathway.
The choice of the anti-HER2 agent will depend on country-specific availability, the specific anti-HER2 therapy previously administered and the relapse-free interval. The optimal sequence of all available anti-HER2 therapies is currently unknown.
The optimal duration of anti-HER2 therapy for MBC (i.e. when to stop these agents) is currently unknown.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,91%,Guideline statement,HER2-positive ABC
31066426-d3e0-491a-a9bf-93f8c282896f,"In patients achieving a complete remission, the optimal duration of maintenance anti-HER2 therapy is unknown and needs to be balanced against treatment toxicity, logistical burden and cost. Stopping anti-HER2 therapy after several years of sustained complete remission may be considered in some patients, particularly if treatment rechallenge is available in case of progression.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,93%,Guideline statement,HER2-positive ABC
c034a882-4069-4475-840c-d076db119947,Patients who have received any type of (neo) adjuvant anti-HER2 therapy should not be excluded from clinical trials for HER2-positive ABC. These patients remain candidates for anti-HER2 therapies.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,100%,Guideline statement,HER2-positive ABC
d68eb224-33e0-4008-a4b2-ea459a6ccdc1,"For highly selected patientsa with ER-positive/HER2-positive ABC, for whom ET + anti-HER2 therapy was chosen as first-line therapy, dual anti-HER2 blockade (with either pertuzumab + trastuzumab or lapatinib + trastuzumab) can be used since it provides a benefit in PFS. This decision must be balanced against the higher side-effects, higher costs and lack of OS benefit so far, as compared with ET + anti-HER2 monotherapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,80%,Guideline statement,HER2-positive ABC
cd55ca47-d827-49d1-85e5-b9f0bb216204,"For patients with ER-positive/HER2-positive ABC, for whom ChT + anti-HER2 therapy was chosen as first-line therapy and provided a benefit, it is reasonable to use ET + anti-HER2 therapy as maintenance therapy after stopping ChT, although this strategy has not been studied in randomised trials.
Duration of maintenance therapy should be until progression, unacceptable toxicity or patient request, and needs to be evaluated in clinical trials.
There are no data to decide between single-agent anti-HER2 or dual blockade to combine with maintenance ET after stopping ChT in ER-positive/HER2-positive ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/B,80%,Guideline statement,HER2-positive ABC
b5ec7b3b-d0ef-485c-85a7-f4a7727137c0,"In the first-line setting, for HER2-positive ABC previously treated (in the adjuvant setting with DFI >12 months) or untreated with trastuzumab, combinations of ChT + trastuzumab are superior to combinations of ChT + lapatinib in terms of PFS and OS.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,95%,Guideline statement,HER2-positive ABC
032b2d5b-865f-4a08-a12b-da59dbd20c97,The standard first-line therapy for patients previously untreated with anti-HER2 therapy is the combination of ChT + trastuzumab and pertuzumab because it has proven to be superior to ChT + trastuzumab in terms of OS in this population. ESMO-MCBS v1.1 score: 4,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,86%,Guideline statement,HER2-positive ABC
a36b1720-26bd-4f65-86df-9b9f747f84b5,"For patients previously treated [in the (neo)adjuvant setting] with anti-HER2 therapy, the combination of ChT + trastuzumab and pertuzumab is an important option for first-line therapy.
Few (88) of these patients were treated in the CLEOPATRA trial and all with a trastuzumab-free interval >12 months.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,76%,Guideline statement,HER2-positive ABC
97aee1bc-33e5-4485-a872-bda9258dcb72,There are currently no data supporting the use of dual blockade with trastuzumab + pertuzumab and ChT beyond progression (i.e. continuing dual blockade beyond progression) and therefore dual blockade should not be given beyond progression outside clinical trials.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/E,86%,Guideline statement,HER2-positive ABC
52730114-cc12-4319-ac49-c7a2913c8827,"In a HER2-positive ABC patient previously untreated with the combination of ChT + trastuzumab + pertuzumab, it is acceptable to use this treatment after first line.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/B,76%,Guideline statement,HER2-positive ABC
b7254782-35df-48c6-b1ec-82296f4d9909,"After first-line trastuzumab-based therapy, T-DM1 provides superior efficacy relative to other HER2-based therapies in the second line (versus lapatinib + capecitabine) and beyond (versus treatment of physician's choice).
T-DM1 should be preferred in patients who have progressed through at least one line of trastuzumab-based therapy, because it provides an OS benefit. ESMO-MCBS v1.1 score: 4","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,88%,Guideline statement,HER2-positive ABC
48b9fa9a-1aad-42b2-8ee6-fe0cc41b3668,"In case of progression on trastuzumab-based therapy, the combination trastuzumab + lapatinib is a reasonable treatment option for some patients. ESMO-MCBS v1.1 score: 4
There are, however, no data on the use of this combination after progression on pertuzumab or T-DM1.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,84%,Guideline statement,HER2-positive ABC
be5b6d72-9890-473d-a6fe-9a36c0ebc45d,"The combination of neratinib + capecitabine was compared with lapatinib + capecitabine as third line or beyond therapy for HER2-positive ABC, showing a marginal benefit in PFS, and with no significant difference in the co-primary end point of OS. There was no comparator arm with trastuzumab + capecitabine, which had previously been demonstrated to give superior OS to lapatinib + capecitabine. Therefore, the combination of neratinib + capecitabine is not recommended for routine clinical practice.
ESMO-MCBS: No manuscript publication; precludes scoring.
Additional studies are needed to clearly establish the potential role of this combination in the treatment of brain metastases, as well as the role of neratinib for ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/D
I/D","90%
90%",Guideline statement,HER2-positive ABC
e237057c-798d-49cb-a371-63f67eb94847,"Trastuzumab deruxtecan (DS-8201) showed important activity in a phase II study in heavily pretreated patients with HER2-positive ABC (median lines of therapy: 6), and is a treatment option in this setting, where approved. Pulmonary toxicity (interstitial lung disease/pneumonitis) can be fatal and requires active surveillance and proper management. ESMO-MCBS v1.1 score: 2.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/B,98%,Guideline statement,HER2-positive ABC
fe7a52c2-2a23-4b87-8ff2-2c9076c20fec,"Dual blockade with tucatinib + trastuzumab + capecitabine showed a small benefit in median PFS (2 months) and median OS (4 months) over trastuzumab + capecitabine in patients previously treated with trastuzumab, pertuzumab and T-DM1, including patients with brain metastases, at the expense of higher toxicity (i.e. diarrhoea). If approved, it can be considered a treatment option in this setting. ESMO-MCBS v1.1 score: 3.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/B,98%,Guideline statement,HER2-positive ABC
e15138cd-d147-4bb8-bf97-0ef1b238eb41,"Margetuximab + ChT showed only a small PFS benefit (1 month) when compared with trastuzumab + ChT for patients pretreated with pertuzumab and T-DM1, and cannot therefore be recommended for routine clinical practice. ESMO-MCBS: No manuscript publication; precludes scoring.
The role of CD16A genotype as a predictor of anti-HER2 antibody efficacy and selection of anti-HER2 agent should be further explored.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,95%,Guideline statement,HER2-positive ABC
10da97ef-3240-4286-ab1a-cd82b6200df3,"Regarding the ChT component of HER2-positive ABC treatment:
When pertuzumab is not given, first-line regimens for HER2-positive ABC can include trastuzumab combined with vinorelbine or a taxane. Differences in toxicity between these regimens should be considered and discussed with the patient in making a final decision.
Other ChT agents can be administered with trastuzumab but are not as well studied and are not preferred.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,88%,Guideline statement,HER2-positive ABC
e97ef99e-cf62-44ca-9546-08902d96df94,"For later lines of therapy, trastuzumab can be administered with several ChT agents, including but not limited to, vinorelbine (if not given in first line), taxanes (if not given in first line), capecitabine, eribulin, liposomal anthracyclines, platinums, gemcitabine or metronomic CM. The decision should be individualised and take into account different toxicity profiles, previous exposure, patient preferences and country availability.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,91%,Guideline statement,HER2-positive ABC
81c60400-cad3-4fab-9168-2fa39302ce4d,"ChT agents to combine with a dual blockade of trastuzumab + pertuzumab are docetaxel [I/A] or paclitaxel [I/B]. Also possible are vinorelbine [II/A], nab-paclitaxel [II/B], capecitabine [I/A] and metronomic ChT for older patients [II/B].","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",See in statement,86%,Guideline statement,HER2-positive ABC
3a1777e0-1ef9-4296-a9dc-a02487e53f46,"In triple-negative ABC patients (regardless of BRCA status) previously treated with anthracyclines with or without taxanes in the (neo)adjuvant setting, carboplatin demonstrated comparable efficacy and a more favourable toxicity profile compared with docetaxel and is, therefore, an important treatment option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,91%,Guideline statement,Triple-negative ABC
f10873d9-b0bd-42a0-8828-84e6d7a2c88e,"For non-BRCA-associated triple-negative ABC, there are no data supporting different or specific ChT recommendations, besides platinum. Therefore, all ChT recommendations for HER2-negative disease also apply for triple-negative ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,98%,Guideline statement,Triple-negative ABC
6cd6a41a-b735-4f24-ad78-fe9aea353874,"The AR is a potential target in triple-negative ABC. There are, however, no standardised methods to assay AR. Limited data suggest a low level of efficacy for AR antagonist agents such as bicalutamide and enzalutamide. At this time, these agents should not be used in routine clinical practice.
More definitive trials are needed, and research efforts must continue to optimise and standardise the determination of AR.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/D,85%,Guideline statement,Triple-negative ABC
bf2b6982-412d-4aaf-8cd8-84069095a0ef,"Atezolizumab + nab-paclitaxel is an option for first-line therapy for PD-L1-positivea triple-negative ABC, either de novo or at least 12 months since (neo)adjuvant ChT. ESMO-MCBS v1.1 score: 3","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,95%,Guideline statement,Triple-negative ABC
b236ad06-18d3-4ccf-a005-ba3c47dd1cb6,Checkpoint inhibitor monotherapy in later lines for triple-negative ABC is not recommended due to low response rates.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/E,89%,Guideline statement,Triple-negative ABC
3efc96af-9044-4195-b5e3-0b00a8eafe96,"Several ongoing trials are evaluating the role of immunotherapy in other ABC subtypes (non-TNBC) and, for the moment, it is not recommended outside clinical trials.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/E,98%,Guideline statement,Triple-negative ABC
52af31c8-3849-4fc4-bffe-12002a55c1bc,"Immunotherapy, with a checkpoint inhibitor, for any biological subtype of ABC should not be used in routine clinical practice outside clinical trials. Several ongoing trials are evaluating the role of this type of treatment in all ABC subtypes.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/D,85%,Guideline statement,Triple-negative ABC
f25e2611-cbfc-4959-b77c-d172ebdd3d8d," For ABC patients, results from germline genetic testing have therapeutic implications and should therefore be performed as early as possible.
Appropriate counselling should be provided to patients and their families if a pathogenic germline mutation is found.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,88%,Genetic testing,Hereditary ABC
7a3a4883-4892-4775-a3a7-dc17a3ed2ccf," At present, only germline mutations in BRCA1/2 have proven clinical utility and therapeutic impact.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Genetic testing,Hereditary ABC
905e2d5e-9909-41fc-81ae-8da9b174138f," Testing for other additional moderate- to high-penetrance genes may be considered, if deemed appropriate by the geneticist/genetic counsellor, in particular because they may have implications for family members. However, it must be clarified to the patient that at present, a mutation in another moderate-/high-penetrance gene has no direct clinical implications for the patients themselves in the setting of ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,100%,Genetic testing,Hereditary ABC
6aa7b375-3823-45e4-9e0b-d9c776ebc15e, The therapeutic implications of somatic BRCA1/2 mutations in breast tumours need to be further explored within a research setting and should not be used for decision making in routine clinical practice.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/E,83%,Genetic testing,Hereditary ABC
6e88b9aa-bb3a-4e57-8039-6a8a44b4270e," In patients with gBRCA-associated triple-negative ABC or endocrine-resistant ABC previously treated with an anthracycline with or without a taxane (in the adjuvant and/or metastatic setting), a platinum regimen is the preferred ChT option, if not previously administered.
All other ChT recommendations are similar to those for sporadic ABC.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,86%,BRCA-associated ABC,Hereditary ABC
3d3c799c-f506-4160-a52d-8253e574d0ea," For patients with a gBRCA mutation, single-agent PARPi (olaparib or talazoparib) is a preferred treatment option for those with triple-negative ABC.
In ER-positive gBRCA-associated ABC, the optimal sequence between a PARPi and ET with or without a CDK4/6 inhibitor is unknown. Given the OS benefit seen with CDK4/6 inhibitors, the panel recommends their use before a PARPi.
Single-agent PARPis (olaparib or talazoparib) are associated with a PFS benefit, improvement in QoL and a favourable toxicity profile. Results suggest that any benefit in OS may be limited to the first-line setting.
ESMO-MCBS v1.1 score: 4","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/A
Expert opinion/B
Expert opinion/B","78%
78%
78%",BRCA-associated ABC,Hereditary ABC
3e2b1bdd-4ed8-4070-90d3-2ac622e1007f," It is unknown how PARPis (olaparib or talazoparib) compare with platinum compounds in this setting, the optimal use with platinum (combined or sequential) and their efficacy in tumours progressing after platinum.
More research is needed to answer questions related to treatment sequencing.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,90%,BRCA-associated ABC,Hereditary ABC
507cf5e4-29f7-429a-9d4a-f826d6a9b0cf," BROCADE3 was the first phase III trial testing a PARPi (veliparib) in gBRCA-mutated MBC that included a platinum. Initial presentation of results showed a small benefit in PFS (1.9 months). However, durable PFS at 3 years was seen in a significant minority (one in four patients) during veliparib maintenance, which could provide patients lacking other maintenance treatment options with ChT-free time. Mature OS data are needed before this regimen can be recommended for routine clinical practice.
ESMO-MCBS: No manuscript publication; precludes scoring.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,98%,BRCA-associated ABC,Hereditary ABC
57882b95-0e53-4405-8f5d-4f322d65ecfb,"Multigene panels, such as those obtained using NGS or other technology on tumour DNA, have not yet proven beneficial in clinical trials for ABC; their impact on outcome remains undefined and should not be used in routine clinical practice.
For patients who are suitable to participate in clinical trials of novel therapies and are readily able/motivated to attend a centre with relevant clinical trials, NGS testing may be used in the context of prospective molecular triage programmes to select patients for therapeutic trials.
Specific tests (as distinguished from broad mutation profiles) are useful and discussed in separate statements; others may play a role in the future as the medicines they are linked with achieve regulatory approval.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,83%,Guideline statement,Precision medicine
88757c2c-1c41-4bc1-9acb-d94e641a2e2b,ctDNA assessment is not recommended for demonstration of disease progression.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,97%,Guideline statement,Precision medicine
d798bf2f-36c0-49b7-a3df-77943cdc1ee4,ctDNA assessment is an option for the detection of PIK3CA mutations for a selection of patients eligible for alpelisib.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,93%,Guideline statement,Precision medicine
5a635de8-1c61-44ce-bf15-b4701684a9f4,"If treatment with the PI3K inhibitor, alpelisib, is available, patients should be tested for PIK3CA mutation (in exon 9 and 20) in a tissue (metastasis or primary) and/or by ctDNA testing in blood.
Patients who do not have an available archival tissue sample and have an uninformative result using a liquid biopsy test could consider undergoing a tumour biopsy for PIK3CA mutation testing.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,100%,Guideline statement,Precision medicine
f476d28c-09fa-4dd9-b62f-98894a05130b,"ESR1 mutation status assessment is not ready for routine clinical practice use and is not recommended, either for demonstration of disease progression or selection of ET (such as a switch from AI to fulvestrant).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,90%,Guideline statement,Precision medicine
c74528ed-d90b-4c4f-98c1-0de2609384e3,PD-L1 status should be tested in cases of first-line triple-negative ABC if treatment with immune checkpoint inhibitors is available.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,97%,Guideline statement,Precision medicine
59389ab7-6d7f-451b-92c8-e938ff217d94,"PD-L1 status is the companion test for the use of the combination of atezolizumab and taxane as first-line therapy for triple-negative ABC, using IHC with the SP142 antibody (Ventana) and a cut-off of 1% of positive staining on immune cells.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,97%,Guideline statement,Precision medicine
ada1f1ca-c578-4488-bae6-3aedec27b29b,"Patients with low (1%-10%) ER-positive (and PgR-positive), HER2-negative ABC should not be considered for ET exclusively.
Patients with low (1%-10%) ER-positive (and PgR-positive), HER2-negative ABC can be considered as patients with triple-negative ABC for clinical trials.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/B,95%,Guideline statement,Precision medicine
046020a7-18d7-408d-a2dc-901d6cdf7033,"If an ABC patient presents with a tumour with MSI-H/MMR-D, treatment with an anti-PD-1 agent is a possible consideration.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,"Yes: 41%
Abstain: 10%
Insufficient data: 49%",Guideline statement,Precision medicine
57335472-df33-4630-9bc6-106c53e8b065,"If an ABC patient presents with a tumour with an NTRK fusion, treatment with a TRKi is a possible consideration.
Patients must be informed about the amount of data available for ABC specifically. Research on the best companion diagnosis tools and techniques is needed. Prospective registries should be created to collect data from all patients treated with these innovative approaches after proper consent.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,"Yes: 29%
Abstain: 24%
Insufficient data: 47%",Guideline statement,Precision medicine
67c808f2-f009-4c95-a0f0-14a3aaeb377c," Radiological assessments are required in patients with persistent and localised pain due to bone metastases to determine whether there are impending or actual pathological fractures. If a fracture of a long bone or vertebrae is likely or has occurred, an orthopaedic assessment is required as the treatment of choice may be surgical stabilisation, which is generally followed by RT. In the absence of a clear fracture risk, RT is the treatment of choice.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,96%,Bone metastases,Specific sites of metastases
a48e9ebf-1967-4770-bf91-9f840c50e79d," Neurological symptoms and signs which suggest the possibility of spinal cord compression must be investigated as a matter of urgency. This requires a full radiological assessment of the potentially affected area as well as adjacent areas of the spine. MRI is the method of choice. An emergency surgical opinion (neurosurgical or orthopaedic) may be required for surgical decompression. If no decompression/stabilisation is feasible or indicated, emergency RT is the treatment of choice and vertebroplasty is also an option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,100%,Bone metastases,Specific sites of metastases
c4b26362-2bcf-44b7-8b00-fa78aa26d194," Regarding the use of bone-targeted agents (bisphosphonate, denosumab), the ABC panel endorses the ESMO CPG99 related to this subject.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",nan,100%,Bone metastases,Specific sites of metastases
5a6074b8-4db4-4775-93fd-989bcc95810d, Patients with a single or a small number of potentially resectable brain metastases should be treated with surgery or radiosurgery. Radiosurgery is also an option for some unresectable brain metastases.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,92%,Brain metastases,Specific sites of metastases
b8f3f9d2-9cb9-4221-b429-978deace4305," If surgery/radiosurgery is performed it may be followed by WBRT, but this should be discussed in detail with the patient, balancing the longer duration of intracranial disease control and the risk of neurocognitive effects.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/C,72%,Brain metastases,Specific sites of metastases
b1661362-4bbc-4443-a8c4-721da8c5687b," Because patients with HER2-positive ABC and brain metastases can live for several years, consideration of long-term toxicity is important and less toxic local therapy options (e.g. stereotactic RT) should be preferred to WBRT, when available and appropriate (e.g. in the setting of a limited number of brain metastases).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,89%,HER2-positive ABC and brain metastases,Specific sites of metastases
3f292bf1-0c4a-4ab1-8b3d-5c0947f9077e," In patients with HER2-positive ABC who develop brain metastases with stable extracranial disease, systemic therapy should not be changed.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/D,95%,HER2-positive ABC and brain metastases,Specific sites of metastases
0852e270-1c9f-4346-ae52-68d07fb864f7," For patients with HER2-positive ABC where brain metastases are the only site of recurrence, the addition of ChT to local therapy is not known to alter the course of the disease and is not recommended.
It is recommended to re-start the anti-HER2 therapy (trastuzumab) if this had been stopped.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/D
I/B","83%
83%",HER2-positive ABC and brain metastases,Specific sites of metastases
39389c49-2bc9-4672-9dce-d5bc8e6b1ec0," For patients with HER2-positive ABC with progressive brain metastases as the predominant site of disease burden, if no further relevant local therapy options are available, a change in systemic therapy is a reasonable option, preferably in clinical trials.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/A,85%,HER2-positive ABC and brain metastases,Specific sites of metastases
a6c2a68c-8ecd-460d-bf67-2700c8cb3f08," Radionecrosis after stereotactic RT for brain metastases is an uncommon complication that may occur, especially with longer survival and follow-up, and in particular in cases of re-irradiation. Differential diagnosis with tumour progression is often difficult. Treatment of symptomatic patients with a course of high-dose steroids is the first treatment of choice. If no response, bevacizumab may be used, as an option to decrease the surrounding oedema, usually at a dose of 7.5 mg/kg every 2 weeks for a median of 4 cycles. Prospective randomised trials are needed to further validate this option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/B,61%,HER2-positive ABC and brain metastases,Specific sites of metastases
52ba2323-30e2-49ff-892c-5780e49ec9c8," There is no accepted standard of care for breast cancer LMD. The choice of treatment (RT, intra-CSF therapy, systemic therapy, supportive care) should consider prognostic evaluation and multidisciplinary discussion.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion,95%,LMD,Specific sites of metastases
e76b3bb3-0a09-4717-87ee-b6ef36b1ff9c," Focal RT should be considered for circumscribed, notably symptomatic lesions.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion,95%,LMD,Specific sites of metastases
129701bb-e92d-40e1-9e75-cc11b0a32186, WBRT can be considered for extensive nodular or symptomatic linear LMD.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion,95%,LMD,Specific sites of metastases
57b6d8ae-896c-49d5-907c-b5028087fe58, Addition of intrathecal to systemic therapy has no OS or QoL advantage and no clinically meaningful effect on CSF progression.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/D,95%,LMD,Specific sites of metastases
e464ddc6-16d7-4ef6-9f3a-4ccdabc03326," Intrathecal therapy can be considered if systemic disease is stable and there is normal CSF flow, when there is evidence of malignant cells in the CSF (type I LMD). Significant toxicity may occur.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion,95%,LMD,Specific sites of metastases
fbb84201-ce74-4e1e-9af5-69fc86945344," Prospective RCTs of local therapy for breast cancer liver metastases are urgently needed since available evidence comes only from series in highly selected patients. Since there are no randomised data supporting the effect of local therapy on survival, every patient must be informed of this when discussing a potential local therapy technique. Local therapy should only be proposed in very selected cases of good PS, with limited liver involvement and no extrahepatic lesions, after adequate systemic therapy has demonstrated control of the disease. Currently, there are no data to select the best technique for the individual patient (surgery, stereotactic RT, intrahepatic ChT, etc.).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,83%,Liver metastases,Specific sites of metastases
1f1efe7a-4a68-4bb0-9fda-91e9be3f7c9a," Malignant pleural effusions require systemic treatment with/without local management.
Thoracentesis for diagnosis should be performed if it is likely that this will change clinical management. False negative results are common.
Drainage is recommended in patients with symptomatic, clinically significant pleural effusion.
Use of an intrapleural catheter or intrapleural administration of talc or drugs (e.g. bleomycin, biological response modifiers) can be helpful.
Clinical trials evaluating the best technique are needed.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","III/A
III/B
III/A
III/B",86%,Malignant pleural effusions,Specific sites of metastases
93a3a9f7-aecd-4201-a78c-4aeb006cfb9a," Due to the high risk of concomitant distant metastases, patients with chest wall or regional (nodal) recurrence should undergo full restaging, including assessment of chest, abdomen and bone.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
6b545c68-24d3-41d9-8fad-94194902fd5a, Chest wall and regional recurrences should be treated with surgical excision when feasible with limited risk of morbidity.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,97%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
982ac57f-6b53-4135-9bbb-af51b1495c6e, Locoregional RT is indicated for patients not previously irradiated.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,97%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
8f3793da-f36e-4a2d-88b1-cce6c63f8414," For patients previously irradiated, re-irradiation of all or part of the chest wall may be considered in selected cases.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,97%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
10eeea6f-7bb1-4d14-ad87-5e4180b387c3," In addition to local therapy (surgery and/or RT), in the absence of distant metastases, the use of systemic therapy (ChT, ET and/or anti-HER2 therapy) should be considered.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,95%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
d2094db4-fffb-4f63-a1c1-89408441018b, ChT after first local or regional recurrence improves long-term outcomes in ER-negative disease and can be used.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,95%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
94dbd7a3-b6d1-4a14-b422-ba16813cd6c3, ET in this setting improves long-term outcomes for ER-positive disease and should be used.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,95%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
92f47d90-c396-4ba2-b532-968bcc033967," The choice of systemic treatment depends on tumour biology, previous treatments, length of DFI and patient-related factors (comorbidities, preferences, etc.).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,95%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
0962bf9b-5736-4265-9a6f-5d4907da8540," In patients with disease not amenable to radical local treatment, the choice of palliative systemic therapy should be made according to principles previously defined for metastatic disease. These patients may still be considered for palliative local therapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/B,97%,Chest wall and regional (nodal) recurrences,Specific sites of metastases
bba46da7-24e7-469e-b48e-25c8cbccbb93," For ER-positive male ABC, which represents the majority of cases, ET is the preferred option unless there is visceral crisis or rapidly progressive disease needing a fast response.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/A,100%,Advanced male breast cancer,Specific populations
5ce3f7f8-7205-4aaa-aeb2-5512cf982f9b," For ER-positive male ABC, tamoxifen is the preferred option.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",IV/B,83%,Advanced male breast cancer,Specific populations
01d99962-5fd3-47b3-a08c-2fd8063fd130," For male patients with ABC who need to receive an AI, a concomitant LHRH agonist or orchidectomy is the preferred option. AI monotherapy may also be considered with close monitoring of response.
Clinical trials are needed in this patient population.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",IV/B,86%,Advanced male breast cancer,Specific populations
1d10d38e-019d-45e5-8161-f9486620ced9,"Before starting any therapy, a core biopsy providing histology and biomarker expression (ER, PgR, HER2, proliferation/grade) is indispensable to guide treatment decisions.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,97%,Guideline statement,LABCa
6a017433-c07f-4264-9f35-2d8a78486ba1,"Since LABC patients have a significant risk of metastatic disease, a full staging work-up, including a complete history, physical examination, laboratory tests and imaging of the chest and abdomen (preferably with a CT scan) and bone before initiation of systemic therapy is highly recommended.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,LABCa
799b4d0b-7dca-4d1d-b3b6-4b1be6c887fc,"PET-CT, if available, may be used (instead of and not in addition to CT scans and a bone scan).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/B,100%,Guideline statement,LABCa
c71ee3df-c97e-43c3-8655-ee85cedea46b,"Systemic therapy (not surgery or RT) should be the initial treatment.
If LABC remains inoperable after systemic therapy and eventual RT, 'palliative' mastectomy should not be done unless the surgery is likely to result in an overall improvement in QoL.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","III/A
Expert opinion/D",100%,Guideline statement,LABCa
a216cdbe-348c-4abf-aa08-608df3da308c,"A combined treatment modality based on a multidisciplinary approach (systemic therapy, surgery and RT) is strongly indicated in the vast majority of cases.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,LABCa
789c7d8e-d69b-4aff-9880-c99f99fe252c,"Options for HR-positive LABC include an anthracycline- and taxane-based ChT regimen, or ET.
The choice of ChT versus ET as initial treatment will depend on tumour (grade, biomarker expression) and patient (menopausal status, PS, comorbidities, preference) considerations.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/A
Expert opinion/A","85%
85%",Guideline statement,LABCa
2d759c04-f5aa-4a3d-87a5-8f486dc4cb86,"For triple-negative LABC, anthracycline- and taxane-based ChT is recommended as initial treatment.
A platinum can be combined with the taxane.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,85%,Guideline statement,LABCa
5585c916-d607-4be5-953a-3ea290fe048f,"For HER2-positive LABC, concurrent taxane and anti-HER2 therapy is recommended since it increases the rate of pCR.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,92%,Guideline statement,LABCa
e18440de-8d4f-420f-891e-4bd831367430,"For HER2-positive LABC, anthracycline-based ChT should be incorporated into the treatment regimen.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,72%,Guideline statement,LABCa
e9023b25-9d63-41ca-bc65-05a6791ce201,"When an anthracycline is given, it should be administered sequentially with the anti-HER2 therapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,87%,Guideline statement,LABCa
d2da6293-5950-4762-a298-88c89aade054,"For patients with HER2-positive LABC (inflammatory or non-inflammatory), without distant metastases, who are in complete remission after appropriate preoperative systemic therapy and appropriate locoregional therapy, and being treated with a potential curative intent, the approved adjuvant duration of 1 year of anti-HER2 therapy should be used.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,85%,Guideline statement,LABCa
4b018746-e9bc-4ae0-b81d-15faafae1b84,"Following effective preoperative systemic therapy with or without RT, surgery will be possible in many patients. This will consist of mastectomy with axillary dissection in the majority of cases, but in selected patients with a good response, BCS may be possible.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,98%,Guideline statement,LABCa
fb61fcb5-b211-4393-895c-1cfaa9d1a764,"In patients with axillary low burden of disease at presentation (previously cN0-cN1) with complete response after systemic treatment (ycN0), SLNB can be an option, provided all the recommendations for sentinel node after primary systemic treatment are followed (i.e. dual tracer, clipping/marking positive nodes, minimum of three sentinel nodes).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",III/B,62%,Guideline statement,LABCa
1809d663-82c1-4cd0-9e0a-2e9ccdf8b96c,"For inflammatory LABC, overall treatment recommendations are similar to those for non-inflammatory LABC, with systemic therapy as first treatment.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,93%,Inflammatory LABC,LABCa
f8d3e41a-6ee1-4219-9843-894942befe24,"Mastectomy with axillary dissection is recommended in almost all cases, even when there is a good response to primary systemic therapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,95%,Inflammatory LABC,LABCa
8ebae4a1-4ba3-4a74-9cb9-a324c8a51b1a,Immediate reconstruction is generally not recommended in patients with inflammatory LABC.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",IV/E,95%,Inflammatory LABC,LABCa
9fe1b536-56c4-4c2b-8411-c6c0de93d8b4,"Locoregional RT (chest wall and lymph nodes) is required, even when a pCR is achieved with systemic therapy.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,98%,Inflammatory LABC,LABCa
5525aebf-f779-45f8-a154-651712be602e,Supportive care allowing safer and more tolerable delivery of appropriate treatments should always be part of the treatment plan.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,Supportive and palliative care
14c0b863-f0f2-45f8-af00-897e75082fc5,"Early introduction of expert palliative care, including effective control of pain and other symptoms, should be a priority.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,Supportive and palliative care
003556fb-71bf-442d-b152-acb035ec6c29,"Access to effective pain treatment (including morphine, which is inexpensive) is necessary for all patients in need of pain relief.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/A,100%,Guideline statement,Supportive and palliative care
0c3a3d06-108b-493b-93c5-6f62525c1e16,"The ABC community is aware of the limitations that are being imposed worldwide, as a consequence of the opioid use disorders in certain areas of the world. The ABC community is united in insisting that cancer patients should not have restrictions placed that will limit their access to adequate pain control.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Guideline statement,Supportive and palliative care
4f2e7cf2-9abb-450a-98b0-34e05bcdecc9,The panel encourages research on the potential role of cannabis to assist with pain and symptom control but strongly stresses that it cannot replace proven medicines such as morphine for adequate pain control.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/C,97%,Guideline statement,Supportive and palliative care
8ca71863-961d-4776-9586-ce95926b4ee1,"Optimally, discussions about patient preferences at the end of life should begin early in the course of metastatic disease. However, when active treatment is no longer able to control widespread and life-threatening disease, and the toxicities of remaining options outweigh the benefits, physicians and other members of the healthcare team should initiate discussions with the patient (and family members/friends, if the patient agrees) about end-of-life care.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,96%,Guideline statement,Supportive and palliative care
1e9af279-3b08-4414-a85c-11ee334b4946," Cancer-related fatigue is frequently experienced by patients with ABC, exerts a deleterious impact on QoL and limits physical, functional, psychological and social well-being. The aetiology of this fatigue is complex; therefore, effective management needs to be multidimensional.
It is important to assess cancer-related fatigue using appropriate PROMs before implementing various non-pharmacological (such as exercise [I, A]), and, if needed, pharmacological interventions [II, B].","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/A
II/B",100%,Management of cancer-related fatigue,Supportive and palliative care
c6014cc6-fb27-4972-a9b7-cb740eb74f16," Neutropaenia is the most common toxicity associated with CDK4/6 inhibition and is not generally associated with febrile neutropaenia, although an increase in infections has been reported. Treatment should be delayed until neutrophils have recovered to at least 1000/ml; dose reduction can also be considered.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,100%,Management of CDK inhibitor-induced neutropaenia,Supportive and palliative care
26214d16-3a94-4929-a208-4af46cb289cb, NIP is an uncommon complication of mTOR inhibition or CDK4/6 inhibition. Patient education is critical to ensure early reporting of respiratory symptoms. Treatment interruption and dose reduction are generally effective for grade 2 symptomatic NIP with the use of systemic steroids and treatment discontinuation for grade 3 or greater toxicity.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,100%,Management of NIP,Supportive and palliative care
24b91b78-3e23-490d-b6ee-cdc6afaf18e5," Treatable causes like pleural effusion, pulmonary emboli, cardiac insufficiency, anaemia or drug toxicity must be ruled out. Patient support is essential. Oxygen is of no use in non-hypoxic patients.
Opioids are the drugs of choice in the palliation of dyspnoea.
Benzodiazepines can be used in patients experiencing anxiety.
Steroids can be effective in dyspnoea caused by lymphangitis carcinomatosis, RT or drug-induced pneumonitis, superior vena cava syndrome, an inflammatory component or in (cancer-induced) obstruction of the airways (in which case laser/stent is to be considered).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/A
II/A
Expert opinion/B",100%,Management of dyspnoea,Supportive and palliative care
fb62400b-1fbc-4d9c-b72b-32722022dda0," ESMO/MASCC guidelines103 are available for the management of ChT-induced and morphine-induced nausea and vomiting, and these are endorsed by the ABC community.
There is a need to study nausea and vomiting related to chronic use of anticancer drugs.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/A,100%,Management of nausea and vomiting,Supportive and palliative care
f027fd38-9551-4f31-8e24-988ee2749e0d," Hyperglycaemia and hyperlipidaemia are common, sub-acute complications of mTOR or PIK3CA inhibition. Evaluation of pre-existing diabetes or hyperglycaemia at baseline is essential. Regular, careful monitoring of glycaemia and lipid panel is needed to identify these toxicities.
Management of grade 1 and 2 hyperglycaemia includes treatment with oral antidiabetics and basal insulin, in accordance with international recommendations for diabetes mellitus treatment. Statins are indicated to treat grade 2 and 3 hypercholesterolaemia, and fibrates should be introduced if the triglyceride level is >500 mg/dl (with attention to possible drug-drug interaction between everolimus and fibrates). Treatment interruption and dose reduction are generally effective for grade 2 and 3 toxicity. Treatment should be discontinued for grade 4 toxicity.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/A,100%,Management of endocrine toxicities from mTOR or PIK3CA inhibition,Supportive and palliative care
abef9d46-9a2e-422d-b922-d4fd508507b9," Steroid mouthwash should be used for the prevention of stomatitis induced by mTOR inhibitors (suggested schedule: 0.5 mg/5 ml dexamethasone, 10 ml to swish x 2 min, then spit out; q.i.d.).","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/B
Expert opinion/A
Expert opinion/A
Expert opinion/B
Expert opinion/B",100%,Management of mucositis/stomatitis,Supportive and palliative care
b0f02f2e-c93f-4ffb-bca2-405abd9c0d61," CIPN is frequent and potentially dose-limiting. Risk factors for neuropathy and pre-existing neuropathy need to be identified.
No medical prevention can currently be recommended.
Drug-related factors (dosing, timing, route) can lower the risk of CIPN.
The use of tight gloves and socks during ChT may help reduce the incidence and severity of CIPN.
There are limited evidence-based treatments for CIPN, with tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, duloxetine, pregabalin and gabapentin being most often used.
High-quality studies are needed to evaluate strategies for the prevention and management of CIPN.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","II/C
I/C
II/B",100%,Management of CIPN,Supportive and palliative care
c977a093-0cb6-497e-834a-3079a0004124," HFS is also described as palmar-plantar erythrodysesthaesia syndrome. Most frequent causes are capecitabine, pegylated liposomal doxorubicin and multikinase inhibitors.
Patients should be instructed about early recognition of HFS.
Drug-related factors (dosing, timing, route) can lower the risk of HFS.
Treatment of hyperkeratosis/fungal infections, comfortable shoes and avoidance of friction and heat are recommended.
Intensive skin care of hands and feet (urea cream/ointment) is recommended.
High-quality studies are needed to evaluate strategies for the prevention and management of HFS.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","Expert opinion/A
II/A",100%,Management of HFS,Supportive and palliative care
0cf68571-2f6a-486b-ae65-46a8020076df," Systemic hormone therapy is generally not recommended to treat postmenopausal symptoms in ABC patients, particularly not in ER-positive disease.
Valid alternatives are:*For postmenopausal symptoms in general: mind-body interventions, physical training and CBT are effective non-pharmacological treatment options.*For hot flushes: venlafaxine, oxybutynin, gabapentin, clonidine and acupuncture are available options.*For sleep disturbances: melatonin.There is no convincing evidence that phytotherapeutic drugs improve postmenopausal symptoms. Possible drug interactions must be considered.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","I/D
I/B
I/B
II/C
I/D",100%,Management of postmenopausal symptoms,Supportive and palliative care
e83a9b1a-2555-4350-8e31-26120c1deed1," Sexuality is an experience on many levels and is not confined to the act of intercourse. Sexuality remains important for many ABC patients. ABC patients frequently experience impaired sexual health and need specific attention. Openly addressing misconceptions and sexual challenges after treatment, as well as educating patients, have been shown to improve QoL. When life expectancy is limited, physical contact, affection, emotional communication and comfort are particularly important. Standardised instruments (questionnaires) may help to assess the grade of impairment.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/n/a,100%,Sexual health,Supportive and palliative care
243443c4-a59c-4751-8b34-11cde66f3798," Dyspareunia is often caused by vaginal dryness.
The first choice for treating vaginal dryness and soreness are hormone-free lubricants and moisturisers (e.g. water-based gel, hyaluronic acid gel).
If hormone-free measures are not effective, low-dose estrogen-containing vaginal medication may be used.
The value of local testosterone application and of invasive measures like vaginal laser or hyaluronic acid injections is still unclear.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.","II/B
II/B","100%
100%",Dyspareunia,Supportive and palliative care
60f42388-ec63-4fe3-89ed-085082d659bd,Alternative therapies (i.e. therapies used instead of scientifically-based medicines) are not recommended in any phase or stage of cancer treatment.,"Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",n/a/E,100%,Guideline statement,Integrative medicine
e30c747d-fac9-4927-afa3-b0ecf7a154de,"Breast cancer centres/units/departments should be aware that the majority of their patients would like to be informed about CIM and that many of them are using it. Physicians should actively ask for information about its use in view of the potential deleterious interactions with specific anticancer therapies. If complementary therapies are not available at the centre, certified contacts should be available to promote referral to practitioners qualified in the therapies people are interested in receiving.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,100%,Guideline statement,Integrative medicine
0dd5af85-05ff-4c74-96d9-d2ac24cebb40,"Some complementary therapies have the potential to reduce disease symptom burden and/or side-effects of anticancer therapies, and therefore improve the QoL of ABC patients.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",Expert opinion/C,100%,Guideline statement,Integrative medicine
c1ad53bb-1190-4f83-8fda-448334b35523,"Evidence suggests beneficial effects of the following methods, which can therefore be used:*Physical exercise/sport (equivalent to 3-5 hours of moderate walking per week) improves QoL, cardiorespiratory fitness, physical performance and fatigue, and it may also improve DFS and OS.*MBSR programmes, hypnosis and yoga may improve QoL and fatigue, and help reduce anxiety, distress and some side-effects of anticancer therapies.*Acupuncture may help against ChT-induced nausea and vomiting, fatigue and hot flushes.","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",I/B,100%,Guideline statement,Integrative medicine
0923ac16-bcb3-4f03-b9c2-6acd1f80b705,"Methods with no or unfavourable effects
The following methods of alternative medicine are not recommended in ABC since available evidence shows no effect at best, or even association with worse outcome:*Antioxidant supplements*Drugs outside the approved indication (e.g. methadone)*Herbs including Chinese herbal medicine*Orthomolecular substances (selenium, zinc, etc.)*Oxygen and ozone therapy*Proteolytic enzymes, thymic peptides*Phytoestrogens (soy food, isoflavones)*High-dose vitamins (vitamin C, D, E, carotenoids, etc.)*L-carnitine, laetrile","Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649.",II/E,100%,Guideline statement,Integrative medicine
243fd947-fc5d-49f5-8be1-e410d5c12f00,"Breast tissue is composed of lobules that are glands involved in milk production, ducts that connect the lobules to the nipple and connective tissue, fatty tissue, and lymphatic tissue.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
9775de32-9112-4658-9a6c-ec4b4ef9d6d7,"Breast cancer occurs when there is an unregulated growth of cells within any of the components of the breast, although this occurs most commonly in the lobules.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
55e8bd89-2233-462a-abb0-e511800029d1,"Although significantly less common, breast cancer can also occur among males.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
21163b4a-a2e3-462a-ab0c-06e51d86db50,Breast cancer develops over time and may go through an in situ phase.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
1bc62e32-fb08-4847-9b60-75840b63a625,Breast cancer incidence and mortality increase proportionally with age.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
68e22295-ec58-41fb-a491-c65dbfa5e93a,"Although the overall incidence of breast cancer is slightly lower in black women than in white women, black women have the highest 5 year breast cancer mortality rate for each known stage at diagnosis.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
4dbf08c7-a0c4-4f59-b4dc-be2feff58473,Younger age at menarche and older age at menopause increases breast cancer risk.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
cb4cc56b-727f-4e12-ba10-0378901be7ee,"Women with a history of breast cancer are at higher risk of developing the disease again, especially if the initial age at diagnosis was less than 40 years of age.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
7b476f49-4fef-4f9b-97ad-1ac982718e73,"Delayed childbearing, smaller family size, decreased duration of breastfeeding,and hormonal contraceptives have been linked to increased breast cancer risk.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
b950411f-1e4c-47e9-a167-8b4762d44c52,Combined estrogen and progestin therapy increases the risk of developing breast cancer.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
b85a6359-118b-456c-bf9d-43164c864e6d,Based on current available information there is evidence to suggest that smoking prior to menopause increases breast cancer risk.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
afacd8d2-9f2b-48f4-9f25-9cffba93ca19,Alcohol consumption has been linked to increased breast cancer risk.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
9b39ed50-315c-4d77-ab11-94d619ea78ac,Breast cancer risk is decreased in women performing regular physicalactivity and in those who consume high amounts of fruits and vegetables.,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
28fa90a8-dbdb-4b86-b258-50a1a99ca97e,"Hereditary breast and ovarian cancer syndrome is usually caused by genetic mutations in one of two BReast CAncer (BRCA) susceptibility genes, BRCA1 and BRCA2.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
83bce0fe-1504-4f5f-9acd-44ccda068ab7,Tumor suppressor genes are essential to the normal biophysiology of human function and development. ,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
9150e8db-0fd3-4288-ae95-beecd170889f,Tumor suppressor genes are key to regulating and inhibiting cell growth and proliferation. ,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
a4754c2f-337c-47d5-9b08-94e9c512323e,"Specific proteins are created from these genes that have numerous functions and specialize in DNA repair, initiating apoptosis, block tumor cell adhesion, and preventing metastasis. ","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
766bd84f-2384-40ac-82b2-92359b391406,Mutations can occur within these genes leading to inappropriate and dysfunctional proteins that are unable to perform effectively. ,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
3c58fb5e-b359-43e0-92e2-11b661331b2e,"Once mutations occur, there is an increased risk of tumor formation and malignancy. ","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
2b09ec19-1833-421e-88f3-fd8508911713,"Specific tumor Breast Cancer Epidemiology, Prevention, and Screening 11 suppressor genes, including the breast cancer genes, BRCA1 and BRCA2, are fundamental in cellular processes through genomic integrity and transcriptional regulation.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
51a0b4d5-c10f-419f-9fc3-b57817a063f0,148 Mutations within these two genes are linked to the development of breast and/or ovarian cancer. ,"Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
023f5b37-3f2e-42ce-b7f6-74ab89111908,"These mutations can occur through an inherited, or sporadic process leading to malignancy.","Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print.",,,,
a0f213fb-bfa5-4f88-b9f8-1f1d8e7c8d06,Cancer of the breast is one of the most common neoplasms and the leading cause of carcinoma deaths in women.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
7edf76c6-0a0b-48ef-82ee-4ec124332d44,Most breast malignancies arise from epithelial tissue and are characterised as carcinomas.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
8cd638a9-9074-42f1-a801-8b6260c161dc,"Breast carcinomas are a diverse group of lesions that differ in microscopic appearance and biologic behavior, although these diverse disorders are often discussed as a single disease.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
6c0c6d63-df0a-41ff-87cc-615fa0b9ec6f,Carcinoma in situ refers to a neoplastoc proliferation that is limited to ducts and lobules by the basement membrane.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
2d9f98a9-79d8-4fda-a349-60fd88997788,This distinction is primarly based upon the growth pattern and cytologic geatures of the lesions.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
52844785-4410-417e-a5b1-3f64101706e4,Invasive carcinoma has penetrated through the basement membrane into the stroma.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
48d37b0c-27a4-4655-b23a-14312b71c7ee,Here cells have the potential to invade into the vascalature and therby reach regional lymph nodes and distant sites.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
083feb34-5fdb-4a88-a095-cba1cfead211,Ductal carcinoma (DCIS) in situ is characterised by a proliferation of abnormal cells confined within the mammary ductal system.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
74128e92-7f96-46cf-a146-86f90aa3a285,DCIS is commonly classified according to architectural and cytological features and cell necrosis as low and intermediate grade and high grade.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
5b992fc5-89d3-4121-a9f4-5699ab47a41e,The comedo type is characterised by prominent necrosis in the center of the involved spaces. ,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
c940d657-58e7-4675-a573-8368c6e1e713,The necrotic material frequenlty becomes calcified.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
b181073e-44f8-42d1-bbc5-94ac4d115339,The cribriform type is characterised by the formation of back to back glands withough intervening stroma.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
c1187001-78e3-46f4-85bd-60392f0aff43,The micropilliary type features small tufts of cells that are oriented perpendicular to the basement membrane of the involved spaces and project into the lumina.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
ee4a79f0-72dc-4352-b198-bff2d374efad,"The papillary type shows intraluminal projections of tumor cells that , in contract to the micropapillary variant, demonstrate fibrovascular cores and thereby constitute true papillations.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
e80506df-2da6-495d-bfbd-3faff6ea202f,"A variant of papillary DCIS, intracystic papillary carcinoma, is characterised by tumour cells that are primarly of exclusively present in a single cystically dilated space.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
870622c5-204b-4b87-99d1-82e72292b325,The solid type is not as well defined as the other subtypes.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
d1ef5d7b-4074-44fd-963a-b61e38c28f62,"Less common variants of DCIS include the ""clinging"" carcinoma, intraductal signet ring cell carcinoma, and cystic hypersecretory duct carcinoma.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
47b986f5-64e6-46b5-85dc-aae7edfe6df8,"High-grade lesions typically exhibit aneuploidy, lack estrogen and progesterone receptors, and have a high proliferative rate, overexpression of the HER2 oncogene, mutations of the p53 tumor suppressor gene with accumulation of its protein product, and angiogenesis in the surrounding stroma.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
61cacada-fa1d-4c95-b752-4465b3e2ff89,"Low-grade lesions are typically diploid and estrogen and progesterone receptor positive, have a low proliferative rate, and rarely (if ever) show abnormalities of the HER2/neu or p53 oncogenes.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
5b820405-7c81-43a2-a13f-913e827346af,Lesions categorized histologically as intermediate grade are also intermediate between the high-grade and low-grade lesions with regard to the frequency of alterations in these biologic markers.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
ea3c20cd-eb78-482f-92b7-5922c6853221,DCIS represents a precursor to invasive carcinoma.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
9103cdb3-5851-423a-a875-39a5b150bb1c,Invasive breast carcinomas consist of several histological subtypes.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
20a752ce-5b75-4f13-a68e-abcd53d0dde9,Infiltrating ductal carcinoma is the most common invasive breast cancer.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
6773ac5c-d7d8-4afb-a0d9-a84376fdb5ac,It is also termed infiltrating carcinoma of no special type or infiltrating carcinoma not otherwise specified.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
8b8d8f23-9269-4c72-a656-342785da32b9,"Infiltrating ductal carcinomas are divided into three grades based on a comination of architectural and cytologic features, usually assessed utilising a scoring system based on three parameters.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
efe44178-5984-4525-bae4-0e4b903dcc19,Well differentiated (grade 1)--Well-differentiated tumors have cells that infi ltrate the stroma as solid nests of glands.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
2075f376-f2da-4014-80c0-284a1c3ed3a2,Moderately differentiated (grade 2)--Moderately differentiated tumors have cells that infi ltrate as solid nests with some glandular differentiation.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
8e7c0b1d-3c95-4437-a51d-73c1a44cc4dc,Poorly differentiated (grade 3)--Poorly differentiated tumors are composed of solid nests of neoplastic cells without evidence of gland formation.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
39dc1e65-a223-4442-abe1-0afa163b5763,Infiltrating lobular carcinoma is the second most common invasive breast cancer.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
67d1c2cd-b963-41c0-9ace-cc121c82203c,"In addition to their different histologic appearance and mammographic characteristics, there are distinct prognostic and biologic differences between Infiltrating lobular and ductal cancers.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
0bfdda07-7637-448a-a47f-3cd47f940542,Infiltrating lobular carcinomas have a higher frequency of bilaterality and multicentricity than Infiltrating ductal carcinomas,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
c9319fb2-96e7-4734-bcc2-fe42d2e461dc,Infiltrating lobular carcinomas arise in older women and are larger and better differentiated tumors.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
2e90f8ea-1b0f-4b27-a061-e84401483127,"As a rule, invasive lobular carcinomas are ER positive, with variant lesions showing occasional variable expression.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
6c2ed508-6a4a-41ea-a6cb-3042bbe9bd5c,"As a group, invasive lobular carcinomas tend to metastasize later than invasive duct carcinomas and spread to unusual locations such as peritoneum, meninges, and the gastrointestinal tract.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
4dc1f44f-a39d-4267-8a1d-539039e349e0,There is an association between mutations in the cadherin (CDH1) gene and invasive lobular breast cancers.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
1e6fb553-24e2-4cc3-909d-647b049c1776,"Other less common invasive breast carcinoma histologies include tubular, mucinous, and medullary carcinomas.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
a2a8cf3f-4f52-42ad-8e78-ab2b8c259995,Tubular carcinoma is characterized by the presence of well-formed tubular or glandular structures Infiltrating the stroma.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
4aba4b5e-86ea-4ac1-9e26-c2dcb24fef4d,"These lesions have a relatively favorable prognosis compared with Infiltrating ductal carcinomas; the natural history is favorable, and metastases are rare.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
dfa04d4d-275a-4ac6-9983-909712f8c9af,"Mucinous carcinomas... These lesions usually have a soft gelatinous appearance on gross examination, and they tend to be well circumscribed.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
dae9e474-f115-4de5-a7b5-cd4537ab0d54,Medullary carcinomas are well circumscribed on macroscopic examination and are often soft and tan brown with areas of hemorrhage or necrosis.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
89f054c5-d060-4810-a307-2a1f995995a4,Medullary and medullary-like carcinomas occur more frequently in younger patients than other types of breast cancer.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
e2b76232-9e26-4b1b-bb14-60a7bb79914f,They are also more frequent in women who inherited mutations of the BRCA-1 gene.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
c3fd880a-d7fc-4c9f-9938-a5d85ed59bba,"Tubulolobular carcinoma is an often unrecognized breast cancer variant that, as the name implies, has hybrid histologic characteristics of tubular and invasive lobular carcinoma with the same cells comprising well-formed glands contiguous with single- file infiltration of stroma.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
e8cf0a5b-3783-4aa9-9ee2-5a453d4f27a8,Invasive micropapillary carcinoma is a particularly aggressive form of cancer that has a proclivity for lymph node metastasis even when small in size.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
03d49f63-53ef-4976-85aa-a71d0001b525,"Metaplastic carcinoma is a well-circumscribed tumor that consists of various combinations of poorly differentiated ductal adenocarcinoma, mesenchymal (sarcomatous), and other epithelial (e.g., squamous cell) components.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
1fa344e1-97ed-408a-8ea3-261ec24f93a6,The rare adenoid cystic carcinoma of the breast has a distinctive histologic pattern that is morphologically identical to adenoid cystic carcinomas found in the salivary glands.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
e8d5b9ef-b770-4bf9-97f8-75c083956720,"The only uniformaly accepted prognostic markers that provide criticial information necessary for treatment decisions are TNM stage, axillary lymph node status, tumor size and grade, hormone receptor status, and HER2 receptor status.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
3642e750-7277-4879-a177-dba7534a58f3,ER positive breast cancer grow in response to the hormone estrogen.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
22944796-7f06-4b5d-ac6f-9ba9fb7a2276,PR positive breast cancers grow in response to the hormone progesterone.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
20dda0a5-de56-41d3-94e6-fcc77c6e4575,HER2 is a protein that is overly expressed in HER2 positive breast cancers.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
884dd300-63ac-4937-bbd0-3b440ed4e20c,...available evidence suggests that ER-/PR-negative tumors have a worse prognosis.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
7c4038cf-ff45-4d02-821c-bd8c1c346767,...ER/PR analysis should be performed routinely in all invasive breast cancers using either immunohistochemistry...,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
abea6d71-0e85-4c2e-9649-03d1fc9206bf,...markers of an elevated proliferative rate correlate with a worse prognosis in untreated patients.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
af9c7242-0416-4e70-876b-e2398b222906,Amplifi cation or overexpression of the HER2 oncogene is present in approximately 20 % of primary invasive breast cancers.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
2bbbc9ff-a9e5-4597-8528-08af1cfb06c1,High levels of HER2 expression (3+ by IHC or an amplifi ed HER2 gene copy number by FISH identify those women who might benefi t from trastuzumab in both the adjuvant and metastatic disease settings.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
d0b1f2e3-9561-4100-a19b-f80fd5c35859,"High levels of HER2 expression (3+ by IHC or an amplifi ed HER2 gene copy number by fluorescence in situ hybridization [FISH]) represent an important predictive factor, identifying those patients who might benefit from treatments that target HER2, such as trastuzumab, in both the adjuvant and metastatic disease settings.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
7755f94c-6bd7-463e-9ab6-093fb4920a62,HER2 overexpression is a negative prognostic factor.,"Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
09e673c7-f660-4ad9-acd3-c427e552a703,"Gene expression profi ling has identifi ed molecular signatures, such as the 21-gene recurrence score (RS, Oncotype Dx (r) ), the Amsterdam 70-gene prognostic profi le (MammaPrint (r) ), and the Rotterdam/Veridex 76-gene signature, that augment conventional prognostic indicators in their ability to predict breast cancer outcome and response to treatment.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
c9a72b4d-587a-49a9-b819-10f99b494916,"The 21-gene recurrence score can be used to predict the risk of recurrence in patients with newly diagnosed, node-negative, estrogen receptor (ER)-positive disease and to identify patients who are likely to benefi t from chemotherapy added to adjuvant endocrine therapy.","Schatten, H. Cell and Molecular Biology of Breast Cancer. New York: Humana Press, 2013. Web.",,,,
